Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
46,611,135
-
Share change
-
+7,776,825
-
Total reported value
-
$90,890,151
-
Put/Call ratio
-
1686%
-
Price per share
-
$1.95
-
Number of holders
-
57
-
Value change
-
+$6,156,453
-
Number of buys
-
37
-
Number of sells
-
27
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q1 2023
As of 31 Mar 2023,
ADC Therapeutics SA - Common Shares (ADCT) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,611,135 shares.
The largest 10 holders included
Redmile Group, LLC, CITADEL ADVISORS LLC, Prosight Management, LP, JPMORGAN CHASE & CO, GOLDMAN SACHS GROUP INC, Sio Capital Management, LLC, MILLENNIUM MANAGEMENT LLC, EVENTIDE ASSET MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., and BANK OF AMERICA CORP /DE/.
This page lists
57
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.